INTRODUCTION
Vascular thrombosis is a known complication of neonatal intensive care medicine. 1 Anticoagulation is sometimes performed by means of heparin or low-molecular-weight heparin (LMWH) treatment, but such treatment requires careful monitoring to insure anticoagulation while minimizing hemorrhagic risks. 1, 2 Prothrombin times (PTs) and activated partial thromboplastin times (aPTTs) do not adequately predict the effect of heparin in neonates, and are not helpful in monitoring LMWH therapy. 1, 3 The only currently available test for monitoring LMWH therapy is the anti-factor Xa (anti-FXa) level. 1 -3 Many neonates receiving anticoagulation treatment have a centrally placed vascular catheter for blood sampling, parenteral nutrition, or medication infusion. However, most of such catheters have heparin-containing solutions run through them continuously or flushed through them intermittently. 4 The presence of heparin in these solutions can contaminate the blood samples drawn through them for coagulation studies. As a consequence, repeated venipuncture samples are recommended for monitoring anticoagulated neonates. 5 However, repeated venipunctures are often technically difficult in these patients, and multiple unsuccessful attempts can result in bleeding complications. We sought to determine whether reliable anti-FXa levels could be obtained from neonates with umbilical artery catheter (UACs) through which heparin-containing solutions were infusing, by using a blood sampling system we developed to reduce heparin contamination.
MATERIALS AND METHODS
We attached an additional port, consisting of a stopcock and T-connector, to the UAC system, permitting no heparin-containing solution to be run, or to be flushed, through this port (Figure 1) . When a blood sample was to be collected, a predetermined lineclearing volume was withdrawn through this new port. After the blood sample was taken, the line-clearing volume of blood was returned to the patient. We first tested this system in vitro by
OBJECTIVE:
Neonates who are treated with low -molecular -weight heparin require repeated venipunctures to monitor anti -factor Xa ( anti -FXa ) levels. Generally, blood withdrawn from umbilical artery catheters ( UACs ) is not useful for such monitoring because heparin in the fluids running through the catheters contaminates the results. We tested methods for collecting blood for anti -FXa levels from UACs through which heparin -containing fluids were running, in an attempt to reduce the need for repeated venipunctures of anticoagulated neonates.
STUDY DESIGN AND METHODS:
A new blood drawing port, through which no heparin was run, was added to the UAC system. Qualifying neonates with UACs were randomized to have anti -FXa levels drawn after line -clearing volumes of 0.5, 3.0, or 4.0 ml.
RESULTS:
Twelve patients with UACs were enrolled and all completed the study with no adverse events. When 0.5, 3.0, or 4.0 ml of blood was cleared from the UAC before withdrawing the test sample, heparin contaminated the test ( antiFXa levels !0.1 U / ml ) in 66%, 16%, and 8% of samples, respectively. Differences between the 0.5 -vs. 3.0 -ml line -clearing volumes and between the 0.5 -vs. 4.0 -ml clearing volumes were significant ( p = 0.0026 and 0.0006, respectively ).
CONCLUSION:
Blood samples for anti -FXa can be drawn from UACs through which heparin -containing solutions are infusing if a port is added through which no heparin -containing fluids are run, a line -clearing volume of at least 4.0 ml is drawn, and a contamination rate of 8% of samples is acceptable. Original Article
colorimetric methods, simulating blood sampling (n=30), which resulted in 100% clearing of color from the samples. A randomized, repeated-measures study was performed on neonates admitted to the neonatal intensive care unit who had an UAC in place through which heparin-containing fluids (1 U/ml) were continuously infusing and intermittently flushed (10 U/ml). The study was approved by the University of Florida Institutional Review Board and informed consent was obtained from a parent of each patient after the nature of the study had been fully explained. Three blood samples were obtained from each patient and were drawn no more frequently than every 8 hours. Once obtained, samples were placed in 1.5-ml Eppindorf tubes containing 1 vol of 3.8% sodium citrate per 9 vol of blood, centrifuged at 3000Âg for 20 minutes, and stored at À80 8C until assayed. Anti-FXa levels were measured by chromogenic assay (Coatest LMW Heparin/ Heparin; Chromogenix, Moindal, Sweden) according to the manufacturer's instructions. 6 Neonates receiving fibrinolytic therapy or systemic anticoagulation were excluded.
Subjects were randomized using prespecified replicates of a pair of Latin squares. Line-clearing volumes of 0.5, 3.0, and 4.0 ml, representing 1.25, 7.5, and 12 times the catheter assembly dead space volume, were randomly assigned a label, then subjects were randomly assigned a treatment sequence. Sample size was determined (n=12) with 0.90 power to detect a difference in proportions greater than 0.70 among the three groups using a twosided test at =0.05. Analysis consisted of a mixed model for modeling binary outcomes with pairwise comparisons at a Bonferroni corrected level 0.05/3. SAS 6.12 software (Cary, NC) was used for all statistical analyses.
RESULTS
Twelve patients were enrolled and all completed the study. The subjects tolerated the procedures well and no adverse events of the study were reported. Results are summarized in the Table 1 . When 0.5, 3.0, or 4.0 ml of blood was withdrawn as line-clearing volumes before the blood was obtained for anti-FXa levels, heparin contamination was detectable (anti-FXA level !0.1 U/ml) in 66%, 16%, and 8% of the samples, respectively. Differences between 0.5-vs. 3.0-ml line-clearing volumes and between 0.5 vs. 4.0 ml were significant ( p=0.0026 and 0.0006, respectively).
DISCUSSION
We performed this study as a step toward reducing the multiple venipunctures currently required to monitor anticoagulation in the neonatal intensive care unit. Neonates who are anticoagulated with heparin commonly have indwelling lines, but contamination of the anti-FXa sample with the heparin infusing through the catheter can lead to an overestimation of the level of anticoagulation. This overestimation might erroneously prompt a decrease in the subsequent LMWH dose.
To avoid heparin contamination of samples drawn from catheters through which heparin is infusing, we placed an additional stopcock Figure 1 . Stopcock ( A) and a two -port (B and C) T-connector were placed just distal to the patient's UAC (arrow labeled ''UAC'' ), and downstream (proximal ) from the heparin -containing fluid infusions (arrow labeled ''Fluids''). Ports B and C were flushed only with normal saline (no heparin ). At the time of anti -FXa sample collection, first, stopcock A was positioned ''off to the patient,'' temporarily stopping heparin -containing fluid infusion to the patient. Secondly, a line -clearing volume of either 0.5, 3, or 4 ml of blood (representing 1.25, 7.5, and 12 times the catheter assembly dead space volume, respectively ) was withdrawn at C, then the T -connector clamped at D, and the anti -FXa blood sample obtained from port B. Thirdly, the clamp at D was released and the lineclearing volume of blood was returned to the patient at C. Finally, stopcock A was positioned ''on to the patient,'' allowing heparin -containing fluid infusion to resume. Port E was provided for administration of any needed medications and for arterial blood gas sampling. *Less than 0.1 U / ml ( no anti -FXa effect detected ). y p < 0.006. z p < 0.0026.
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Blood Samples for Anti-Factor Xa Quantification and T-connector through which no heparin is run. However, when we drew back only a 0.5-ml line-clearing volume through this system prior to obtaining the sample, 66% of the samples had detectable heparin contamination (anti-FXa level >0.1 U/ml). Less heparin contamination resulted when 3.0 ml was cleared through the line, and when 4.0 ml was cleared, only one sample had detectable anti-FXa. (The line-clearing volumes were invariably returned to the patients immediately, and no adverse events were observed.)
The single sample where we used this system, drew back 4.0 ml, and still detected anti-FXa activity was from a patient who was receiving prostaglandin E1 (PGE) by continuous infusion (Table 1 , ID 4). PGE has known anticoagulant effects in adults, 7, 8 but the mechanism is not known. How PGE affects anti-FXa levels in neonates is not known. Perhaps the detectable anti-FXa levels in patient 4 were an effect of PGE rather than a failure of the method. However, even if the method has an inherent failure rate of 8%, this system could have advantages for certain anticoagulated neonatal patients over the current approach of repeated venipunctures.
Our study is the first to measure anti-FXa levels drawn from central catheters through which heparin-containing solutions were running. Other investigators have reported methods for drawing less sensitive tests, such as PT, PTT, and thrombin times, employing differing line-clearing volumes. In canines, a line-clearing volume of five times the catheter dead space volume resulted in reliable correlation among PT, PTT, and thrombin time samples obtained by venipuncture versus catheter. 9 Serial measurements of PT and aPTT obtained from heparinized jugular catheters in canines following a line-clearing volume of 12 times catheter dead space volume versus venipuncture showed similar mean values between groups. 10 In human neonates, PT, aPTT, and antithrombin levels were drawn from UACs infusing either no heparin or 1 U heparin/ml. When a 4-ml line-clearing volume was used, no significant differences were observed between the groups. 4 These studies suggest that coagulation tests can be drawn from indwelling catheters if the line-clearing volume is adequate.
Analogous studies with adult human subjects report mixed results. PT and aPTT values measured in samples from venipuncture versus heparinized central catheters showed significant differences for aPTT using clearing with four times, but not six times, the dead space volume. 11 PT, aPTT, and fibrinogen measured in samples drawn by venipuncture versus sampling immediately after flushing Hickman catheters with heparinized saline resulted in significant differences at all line-clearing volumes, suggesting than flushing a catheter with heparin just prior to sampling contaminates coagulation tests. 12 In conclusion, we report a method by which anti-FXa levels can be obtained through UACs, with a relatively low rate of heparin contamination. Perhaps this method could substitute for a certain number of the venipunctures otherwise needed to monitor anticoagulated neonates.
